Exicure reveals positive data from XCUR17 clinical trial for Psoriasis
Category: #health  By Paroma Bhattacharya  Date: 2019-10-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Exicure reveals positive data from XCUR17 clinical trial for Psoriasis

Clinical trials play a vital role in developing new treatments that could immensely improve a person’s living. Today, researchers and pharmaceutical company are working hard for making breakthroughs in psoriasis treatments.

Exicure Inc. is one such gene-regulating and immunomodulatory drug developer who has recently announced positive clinical results from its drug candidate XCUR17 in psoriasis at the 15th Annual Meeting of the OTS (Oligonucleotide Therapeutics Society) held in Munich.

Reportedly, Dr. David Giljohann, Chief Executive Officer, Exicure, presented the clinical data of XCUR17 at the session of Oligonucleotides Clinical Studies.

Sources close to the study claim that all enrolled patients received daily application of three strengths of XCUR17 vehicle gel and gel to different affected skin areas for twenty-five days. Biopsies were collected from the affected areas following 25-days of treatment as well as from lesional and nonlesional skin at baseline.

Clinical findings related with psoriasis-linked markers and histological variations from biopsies offered by patients showed that in the XCUR17 treatment:

  • There was a decrease in the levels of inflammation markers downstream and psoriasis of XCUR17's target, IL-17RA.
  • There was a substantial decrease in keratin 16 expression which is a key marker of psoriasis.
  • There was a reduction in the major inflammatory markers interleukin 36A, beta-defensin 4A and interleukin 19, versus psoriatic skin at baseline.
  • It showed clinical improvements that matched decreases in epidermal thickness and keratin 16 protein.

Prior to these attained outcomes, on 17 December 2018, Exicure had announced top-line results from Phase 1 trial assessing XCUR17 in patients who has mild-to-moderate chronic plaque psoriasis.

At that time, the highest strength XCUR17 gel indicated a statistically meaningful improvement in psoriasis affected skin. Such findings from the Phase 1 trial showed that SNA-based drugs like XCUR17 may use effectively in treating psoriasis.

Source Credit - https://www.businesswire.com/news/home/20191016005268/en/Exicure-Presents-Positive-Biomarker-Results-Clinical-Trial



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
By Paroma Bhattacharya

Mirati Therapeutics, an oncology company that engages in the development of targeted therapies, recently released its clinical trial results for MRTX849. Reportedly, MRTX849 is a KRAS G12C inhibitor and the data from P...

Best Buy to offer free next-day delivery feature on various products
Best Buy to offer free next-day delivery feature on various products
By Paroma Bhattacharya

Online retailers are always launching new and attractive deals during the holiday season, as it grosses the highest sale time for the year. Several retailer rollout out attractive offers, such as discounts or complimen...

Nature Tech Corp partners with Aldevron for gene therapy manufacturing
Nature Tech Corp partners with Aldevron for gene therapy manufacturing
By Paroma Bhattacharya

The global cell and gene therapy sector is expected to witness a thriving period of growth over the forthcoming years. In fact, owing to the favorable growth conditions across the industry, numerous biotechnology and p...